0	2	In	in	FW
3	7	vivo	vivo	FW
8	18	inhibition	inhibition	NN
19	21	of	of	IN
22	30	NF-kappa	NF-kappa	NNP
31	32	B	B	NNP
33	35	in	in	IN
36	45	T-lineage	T-lineage	NNP
46	51	cells	cell	NNS
52	57	leads	lead	VBZ
58	60	to	to	TO
61	62	a	a	DT
63	71	dramatic	dramatic	JJ
72	80	decrease	decrease	NN
81	83	in	in	IN
84	88	cell	cell	NN
89	102	proliferation	proliferation	NN
103	106	and	and	CC
107	115	cytokine	cytokine	NN
116	126	production	production	NN
127	130	and	and	CC
131	133	to	to	TO
134	143	increased	increase	VBN
144	148	cell	cell	NN
149	158	apoptosis	apoptosis	NN
159	161	in	in	IN
162	170	response	response	NN
171	173	to	to	TO
174	183	mitogenic	mitogenic	JJ
184	191	stimuli	stimulus	NNS
191	192	,	,	,
193	196	but	but	CC
197	200	not	not	RB
201	203	to	to	TO
204	212	abnormal	abnormal	JJ
213	225	thymopoiesis	thymopoiesis	NN
225	226	.	.	.

228	230	To	to	TO
231	241	understand	understand	VB
242	245	the	the	DT
246	250	role	role	NN
251	253	of	of	IN
254	262	NF-kappa	NF-kappa	NNP
263	264	B	B	NNP
265	274	complexes	complex	NNS
275	277	in	in	IN
278	279	T	t	NN
280	284	cell	cell	NN
285	296	development	development	NN
297	300	and	and	CC
301	311	activation	activation	NN
311	312	,	,	,
313	315	we	we	PRP
316	320	have	have	VBP
321	330	generated	generate	VBN
331	341	transgenic	transgenic	JJ
342	346	mice	mouse	NNS
347	349	in	in	IN
350	355	which	which	WDT
356	360	RelA	RelA	NNP
361	364	and	and	CC
365	370	c-Rel	c-rel	NN
371	380	complexes	complex	NNS
381	385	were	be	VBD
386	397	selectively	selectively	RB
398	407	inhibited	inhibit	VBN
408	410	in	in	IN
411	414	the	the	DT
415	424	T-lineage	t-lineage	NN
425	430	cells	cell	NNS
431	433	by	by	IN
434	442	specific	specific	JJ
443	453	expression	expression	NN
454	456	of	of	IN
457	458	a	a	DT
459	473	trans-dominant	trans-dominant	JJ
474	478	form	form	NN
479	481	of	of	IN
482	483	I	i	NN
484	489	kappa	kappa	NN
490	491	B	B	NNP
492	497	alpha	alpha	NN
497	498	.	.	.

499	508	Transgene	Transgene	NNP
509	519	expression	expression	NN
520	523	did	do	VBD
524	527	not	not	RB
528	534	affect	affect	VB
535	538	the	the	DT
539	545	thymic	thymic	JJ
546	557	development	development	NN
557	558	,	,	,
559	562	but	but	CC
563	566	led	lead	VBD
567	569	to	to	TO
570	577	lowered	lowered	JJ
578	585	numbers	number	NNS
586	588	of	of	IN
589	596	splenic	splenic	JJ
597	598	T	t	NN
599	604	cells	cell	NNS
605	608	and	and	CC
609	611	to	to	TO
612	613	a	a	DT
614	622	dramatic	dramatic	JJ
623	631	decrease	decrease	NN
632	634	in	in	IN
635	638	the	the	DT
639	641	ex	ex	FW
642	646	vivo	vivo	FW
647	660	proliferative	proliferative	JJ
661	669	response	response	NN
670	672	of	of	IN
673	680	splenic	splenic	JJ
681	682	T	t	NN
683	694	lymphocytes	lymphocyte	NNS
694	695	.	.	.

696	704	Analysis	Analysis	NNP
705	707	of	of	IN
708	712	IL-2	IL-2	NNP
713	716	and	and	CC
717	722	IL-2R	IL-2R	NNP
723	728	alpha	alpha	NN
729	739	expression	expression	NN
740	752	demonstrated	demonstrate	VBD
753	757	that	that	IN
758	761	the	the	DT
762	774	perturbation	perturbation	NN
775	777	of	of	IN
778	781	the	the	DT
782	795	proliferation	proliferation	NN
796	804	response	response	NN
805	808	was	be	VBD
809	812	not	not	RB
813	825	attributable	attributable	JJ
826	828	to	to	TO
829	831	an	an	DT
832	840	abnormal	abnormal	JJ
841	851	expression	expression	NN
852	854	of	of	IN
855	860	these	these	DT
861	866	genes	gene	NNS
866	867	.	.	.

868	870	In	in	IN
871	879	contrast	contrast	NN
879	880	,	,	,
881	891	expression	expression	NN
892	894	of	of	IN
895	899	IL-4	il-4	NN
899	900	,	,	,
901	906	IL-10	IL-10	NNP
906	907	,	,	,
908	911	and	and	CC
912	921	IFN-gamma	IFN-gamma	NNP
922	925	was	be	VBD
926	934	strongly	strongly	RB
935	944	inhibited	inhibit	VBN
945	947	in	in	IN
948	951	the	the	DT
952	962	transgenic	transgenic	JJ
963	964	T	t	NN
965	970	cells	cell	NNS
970	971	.	.	.

972	975	The	the	DT
976	989	proliferative	proliferative	JJ
990	1000	deficiency	deficiency	NN
1001	1003	of	of	IN
1004	1007	the	the	DT
1008	1018	transgenic	transgenic	JJ
1019	1020	T	t	NN
1021	1026	cells	cell	NNS
1027	1030	was	be	VBD
1031	1041	associated	associate	VBN
1042	1046	with	with	IN
1047	1049	an	an	DT
1050	1059	increased	increase	VBN
1060	1069	apoptosis	apoptosis	NN
1069	1070	.	.	.

1071	1076	These	these	DT
1077	1084	results	result	NNS
1085	1090	point	point	VBP
1091	1094	out	out	RP
1095	1098	the	the	DT
1099	1110	involvement	involvement	NN
1111	1113	of	of	IN
1114	1122	NF-kappa	NF-kappa	NNP
1123	1128	B/Rel	B/Rel	NNP
1129	1135	family	family	NN
1136	1144	proteins	protein	NNS
1145	1147	in	in	IN
1148	1154	growth	growth	NN
1155	1164	signaling	signaling	NN
1165	1173	pathways	pathway	NNS
1174	1176	by	by	IN
1177	1183	either	either	CC
1184	1194	regulating	regulate	VBG
1195	1203	proteins	protein	NNS
1204	1212	involved	involve	VBN
1213	1215	in	in	IN
1216	1219	the	the	DT
1220	1224	IL-2	il-2	NN
1225	1234	signaling	signaling	NN
1235	1237	or	or	CC
1238	1240	by	by	IN
1241	1253	functionally	functionally	RB
1254	1265	interfering	interfere	VBG
1266	1270	with	with	IN
1271	1274	the	the	DT
1275	1279	cell	cell	NN
1280	1285	cycle	cycle	NN
1286	1297	progression	progression	NN
1297	1298	.	.	.